These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9559790)

  • 1. Relationship between didanosine exposure and surrogate marker response in human immunodeficiency virus-infected outpatients.
    Adams JM; Shelton MJ; Hewitt RG; Grasela TH; DeRemer M; Morse GD
    Antimicrob Agents Chemother; 1998 Apr; 42(4):821-6. PubMed ID: 9559790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. Pediatric AIDS Clinical Trials Group Protocol 144 Study Team.
    Stevens RC; Rodman JH; Yong FH; Carey V; Knupp CA; Frenkel LM
    AIDS Res Hum Retroviruses; 2000 Mar; 16(5):415-21. PubMed ID: 10772527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects.
    Cimoch PJ; Lavelle J; Pollard R; Griffy KG; Wong R; Tarnowski TL; Casserella S; Jung D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):227-34. PubMed ID: 9495222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections.
    Morse GD; Fischl MA; Shelton MJ; Borin MT; Driver MR; DeRemer M; Lee K; Wajszczuk CP
    Antimicrob Agents Chemother; 1996 Mar; 40(3):767-71. PubMed ID: 8851608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of high-dose oral ganciclovir on didanosine disposition in human immunodeficiency virus (HIV)-positive patients.
    Jung D; Griffy K; Dorr A; Raschke R; Tarnowski TL; Hulse J; Kates RE
    J Clin Pharmacol; 1998 Nov; 38(11):1057-62. PubMed ID: 9824788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
    Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.
    Japour AJ; Lertora JJ; Meehan PM; Erice A; Connor JD; Griffith BP; Clax PA; Holden-Wiltse J; Hussey S; Walesky M; Cooney E; Pollard R; Timpone J; McLaren C; Johanneson N; Wood K; Booth D; Bassiakos Y; Crumpacker CS
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Nov; 13(3):235-46. PubMed ID: 8898668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of didanosine in patients with human immunodeficiency virus infection.
    Harb GE; Mandema JW; Delahunty T; Benowitz NB; Coleman R; Sheiner LB; Jacobson MA
    J Infect Dis; 1996 Jan; 173(1):273. PubMed ID: 8537676
    [No Abstract]   [Full Text] [Related]  

  • 9. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
    J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients.
    Bouazza N; Tréluyer JM; Msellati P; Van de Perre P; Diagbouga S; Nacro B; Hien H; Zoure E; Rouet F; Ouiminga A; Blanche S; Hirt D; Urien S
    AIDS; 2013 Mar; 27(5):761-8. PubMed ID: 23719348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of absorption of didanosine after rectal administration in human immunodeficiency virus-infected patients.
    Wintergerst U; Rolinski B; Sölder B; Bogner JR; Wolf E; Jäger H; Roscher AA; Belohradsky BH
    Antimicrob Agents Chemother; 1999 Mar; 43(3):699-701. PubMed ID: 10049294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of oral ganciclovir capsules in HIV-infected persons.
    Griffy KG
    AIDS; 1996 Dec; 10 Suppl 4():S3-6. PubMed ID: 9110063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection.
    Morse GD; Fischl MA; Shelton MJ; Cox SR; Driver M; DeRemer M; Freimuth WW
    Antimicrob Agents Chemother; 1997 Jan; 41(1):169-74. PubMed ID: 8980774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of CD4 lymphocytes and clinical consequences of treatment using ddI or ddC in patients with advanced HIV infection.
    Goldman AI; Carlin BP; Crane LR; Launer C; Korvick JA; Deyton L; Abrams DI
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Feb; 11(2):161-9. PubMed ID: 8556398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected children.
    King JR; Nachman S; Yogev R; Hodge J; Aldrovandi G; Damle B; Smith E; Wiznia A; Acosta EP
    Antivir Ther; 2002 Dec; 7(4):267-70. PubMed ID: 12553481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Penetration of didanosine in semen of HIV-1-infected men.
    Cruciani M; Liuzzi G; Chirianni A; Audagnotto S; Bonora S; Di Biagio A; Sinicco A; Bassetti M; Gatti G
    J Antimicrob Chemother; 2006 Jun; 57(6):1244-7. PubMed ID: 16556633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic analysis of didanosine (2',3'-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-related complex.
    Pai SM; Shukla UA; Grasela TH; Knupp CA; Dolin R; Valentine FT; McLaren C; Liebman HA; Martin RR; Pittman KA
    J Clin Pharmacol; 1992 Mar; 32(3):242-7. PubMed ID: 1564128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus--infected pregnant women and their neonates: an AIDS clinical trials group study.
    Wang Y; Livingston E; Patil S; McKinney RE; Bardeguez AD; Gandia J; O'Sullivan MJ; Clax P; Huang S; Unadkat JD
    J Infect Dis; 1999 Nov; 180(5):1536-41. PubMed ID: 10515813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children.
    Balis FM; Pizzo PA; Butler KM; Hawkins ME; Brouwers P; Husson RN; Jacobsen F; Blaney SM; Gress J; Jarosinski P
    J Infect Dis; 1992 Jan; 165(1):99-104. PubMed ID: 1727902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals.
    Hoetelmans RM; van Heeswijk RP; Profijt M; Mulder JW; Meenhorst PL; Lange JM; Reiss P; Beijnen JH
    AIDS; 1998 Dec; 12(17):F211-6. PubMed ID: 9863862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.